KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measure.

J You, J You, B Xu, Z Zhou

ESMO Open 11(11) 108602

PMID42901049
PMCIDPMC13717858
DOI10.1016/j.esmoop.2026.108602
发表日期2026-10-20
入排依据:已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。
摘要

摘要

AIM: Whether intensity-modulated proton therapy (IMPT) offers measurable clinical benefits over intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer remains debated. METHODS: We pooled data from two phase III randomized trials and one matched cohort study comparing IMPT with IMRT and analyzed disease-control, survival, acute toxicity, and nutritional outcomes. RESULTS: The hazard ratio for locoregional recurrence was 1.37 [95% confidence interval (CI) 0.56-3.36, I2 = 0%]; for progression-free survival, 0.90 (95% CI 0.61-1.33, I2 = 0%); and for overall survival, 0.79 (95% CI 0.32-1.98, I2 = 47%). Acute grade 3 dysphagia occurred in 24% of patients receiving IMPT, compared with 40.9% receiving IMRT [risk ratio (RR) 0.65, 95% CI 0.51-0.84, I2 = 0%]. Grade 3 xerostomia or oral/pharyngeal dryness occurred in 19.9% and 32.5%, respectively (RR 0.72, 95% CI 0.54-0.95, I2 = 0%). Exploratory nutritional outcomes showed no definitive benefit, including 12-month gastrostomy dependence (RR 0.32, 95% CI 0.08-1.28, I2 = 0%), weight loss ≥20% (RR 1.05, 95% CI 0.12-9.38, I2 = 85.7%), and composite nutritional endpoints (RR 0.92, 95% CI 0.12-7.07, I2 = 87.7%). CONCLUSIONS: IMPT's primary advantage is reducing acute toxicity, not improving efficacy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。